Providence First Trust’s iShares Biotechnology ETF IBB Stock Holding History

Providence First Trust’s Portfolio IBB Stock Details IBB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-9,053	Closed	-$1.24M	–	99
2024 Q1	$1.24M	Sell	9,053 -500	-5%	-$68.3K	0.54%	52
2023 Q4	$1.3M	Sell	9,553 -87	-0.9%	-$10.6K	0.64%	45
2023 Q3	$1.18M	Sell	9,640 -3,874	-29%	-$493K	0.66%	44
2023 Q2	$1.72M	Sell	13,514 -2,011	-13%	-$261K	0.94%	39
2023 Q1	$2.01M	Sell	15,525 -178	-1%	-$23.3K	1.15%	31
2022 Q4	$2.06M	Hold	15,703	–	–	1.21%	30
2022 Q3	$1.84M	Sell	15,703 -1,015	-6%	-$126K	1.12%	35
2022 Q2	$1.97M	Hold	16,718	–	–	1.11%	35
2022 Q1	$2.18M	Hold	16,718	–	–	1.04%	36
2021 Q4	$2.55M	Hold	16,718	–	–	1.15%	32
2021 Q3	$2.7M	Hold	16,718	–	–	1.28%	30
2021 Q2	$2.74M	Hold	16,718	–	–	1.29%	33
2021 Q1	$2.52M	Buy	+16,718	New	+$2.66M	1.24%	31

Other funds holding IBB

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Commerce Bank Kansas City, Missouri $20.7B AUM 23.76% 1-Year Est. Return

Providence First Trust's IBB Position: Q2 2024 in Review

Providence First Trust sold out of iShares Biotechnology ETF (IBB) in Q2 2024, closing a stake of 9,053 shares — an estimated $1.24M sold.

Providence First Trust first reported a position in IBB in Q1 2021 and held it in 13 quarters. The position peaked at $2.74M in Q2 2021. 894 funds tracked by Wall St. Rank hold IBB as of Q2 2024.

Providence First Trust reported no remaining iShares Biotechnology ETF position as of Q2 2024 after selling out during the quarter.
Providence First Trust sold 9,053 iShares Biotechnology ETF shares in Q2 2024, an estimated $1.24M.
Providence First Trust first reported a position in iShares Biotechnology ETF in Q1 2021 and held it in 13 quarters.
Providence First Trust's iShares Biotechnology ETF position peaked at $2.74M in Q2 2021.
894 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q2 2024.

Based on Providence First Trust's 13F filing for Q2 2024, filed 1 Aug 2024.